October 12, 2012

Reinventing Metformin


Metformin is an insulin-sensitizing drug that is possibly the most common drug used by diabetes patients worldwide. It was initially FDA approved for the US in 1994, but it has been used in other countries for decades. It’s time somebody slapped some new tread on this old tire. Boston Therapeutics has reinvented metformin. The drug is named PAZAMET.

The overall benefits of metformin include enhancing insulin sensitivity, preventing the cardiovascular complications of diabetes, and minimizing weight gain. So what’s the problem with good ol’ metformin? Two common complaints from people who take the drug dislike the “fishy” smell and the  unpleasant aftertaste.

For good measure, the  innovators at Boston Therapeutics have created a metformin that is chewable. The reason that this appeals to people with Type 2 diabetes is a sad but true fact. No longer is Type 2 diabetes called “adult onset diabetes”. Whether you are an adult and can swallow a pill or a child who prefers to chew it, this adds market value to the ever growing market share PAZMET could capture. It’s a better tasting, better smelling, chewable metformin.

Renovating the blueprint of metformin, Boston Therapeutics has submitted a petition to file an Abbreviated New Drug Application (ANDA) for this drug.  An ANDA is an application for a U.S. generic drug approval for an existing licensed medication or FDA-approved drug. If all goes as swiftly as the permission to submit the ANDA for PAZAMET, we could see it stabilizing post meal blood glucose levels with SUGARDOWN sooner than later.

Boston Therapeutics continues to innovate, renovate, and facilitate better ways to treat diabetes. If patient compliance (customer satisfaction) is any barometer of success, Boston Therapeutics is well on their way to dominate and celebrate their stronghold as a staple in diabetes treatment protocol.

Visit Your Diabetes Health for more resources about health.